ASCO GU 2018 Renal Cancer

Viewing 1-20 of 68 articles

ASCO GU 2018: The CLEAR study: A Phase 3 Trial to Compare Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-line Treatment of Patients with Metastatic Renal Cell Carcinoma

ASCO GU 2018: Self-reported Quality of Life as a Predictor of Survival in Renal Cell Carcinoma

ASCO GU 2018: Treatment Facility Volume and Survival in Patients with metastatic Renal Cell Carcinoma

ASCO GU 2018: Carcinomas of the Renal Medulla: A Comprehensive Genomic Profiling Study

ASCO GU 2018: Association of Dividing Pathologically Upstaged T3a Renal Cell Carcinoma with Improved Alignment of Outcomes: A Call for TMN Revision

ASCO GU 2018: A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy

ASCO GU 2018: Treatment trends of localized renal cell carcinoma by hospital type: A NCDB analysis

ASCO GU 2018: Effects of Patient Gender on Urologist Decision-Making Regarding Treatment of the Localized Renal Mass Introduction and Objective

ASCO GU 2018: Systemic Immune Inflammation Index and Treatment Response in Patients with Metastatic Renal Cell Cancer

ASCO GU 2018: Does Treatment Approach for Small Renal Masses Affect Survival in Patients 70 Years Old?

ASCO GU 2018: Outcomes and Patterns of Disease Progression in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab

ASCO GU 2018: The Impact of Facility Case Volume on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in The Targeted Therapy Era

ASCO GU 2018: Impact of Intravenous Acetaminophen on Outcomes following Radical Nephrectomy

ASCO GU 2018: Defining Individual Recurrence Risk Following Surgery for High Risk Non-Metastatic Renal Cell Carcinoma

ASCO GU 2018: Utilization and Survival Implications of a Delayed Approach to Targeted Therapy for Metastatic Renal Cell Carcinoma: A Nationwide Cancer Registry Study

ASCO GU 2018: Imaging Modalities Used for Follow-Up of Localized Renal Cell Carcinoma and Subsequent Effect on Overall Survival after Recurrence: RECUR-Database Analysis

ASCO GU 2018: Title Dose Escalation of Cabozantinib as a Viable Option for the Treatment of mRCC

ASCO GU 2018: S-TRAC trial: Sensitivity Analyses of Disease-Free Survival

ASCO GU 2018: High Dose Interleukin-2 and Response in 944 Patients with Metastatic Renal Cell Cancer (RCC): Data From the PROCLAIM Registry

ASCO GU 2018: Differential Expressions of PD-1, PD-L1, and PD-L2 Between the Primary and Metastatic Sites in Renal Cell Carcinoma

1
2
3
4